Clinical research for anti-CD7 U-CAR-T bridging HST for CD7+ T/NK hematologic malignances

Clinical research for anti-CD7 U-CAR-T bridging HST for CD7+ T/NK hematologic malignances: a multicenter, uncontrolled trial

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900025311

Enrollment

Unknown

Registered

2019-08-22

Start date

2019-09-20

Completion date

Unknown

Last updated

2019-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

refractory/relapse CD7+ T/NK cell hematology malignancies

Interventions

1:infusion of anti-CD7 UCART cells

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. aged 18 to 70 years, male or female; 2. patients with CD7 positive refractory/relapse T/NK hematologic malignancies, with no effective treatment options; 3. projected survival of > 3 months; 4. ECOG <= 2; 5. transplant conditions are met

Exclusion criteria

Exclusion criteria: 1. uncontrolled positive infection; 2. prior treatment with any other cellular immunotherapy; 3. of HIV, HBV, HCV positive; 4. dysfunction of heart, brain or other important organs.

Design outcomes

Primary

Measure	Time frame
3 weeks the ratio of bone marrow blast cells;1 month measurable lesion size and SUV uptake value;	—

Secondary

Measure	Time frame
three months overall response rate;	—

Countries

China

Contacts

Public ContactXi Zhang

The Hematology Department of the Second Affiliated Hospital of the Army Medical University

zhangxxi@sina.com+86 13808310064

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 18, 2026